Citations 1
Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia
Patnaik, Mrinal M. , Sallman, David A. , Mangaonkar, Abhishek A. , Heuer, Rachel, Hirvela, Jeffery, Zblewski, Darci, Al‐Kali, Aref , Binder, Moritz , Balasis, Maria E. , Newman, Hannah , Letson, Christopher T. , Gangat, Naseema , Komrokji, Rami S. , Tefferi, Ayalew , Lo, Adrian , Shih, Ted, Durrant, Cameron, Padron, Eric , Binder, Moritz , Komrokji, Rami S , Balasis, Maria , Newman, Hannah , Kruer, Traci , List, Alan F.
Blood | April 15, 2020 | Volume: 136 | Issue: 7 | Pages: 909-913
In this phase 1 trial, inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) was associated with clinically meaningful responses in 5 of 15 patients with relapsed or refractory chronic myelomonocytic leukemia (CMML). Preliminary data suggest that this approach may be tractable in CMML bearing activating NRAS mutations.